GlobalData on MSN

BioInvent’s mAb plus Keytruda boosts ORR in mid-stage ovarian cancer trial

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...
Yahoo

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...
STAT

Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
BioWorld

Items Tagged with 'PD-1/VEGF bispecific antibodies'

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...